PRO-C3 is found to be released by TGF-β stimulated CAFs in vitro [83], and high PRO-C3 in pre-treatment serum has been shown to predict poor overall survival in metastatic melanoma patients treated with anti-CTLA-4 or anti-PD-1 therapy [83–85]. This evidence concerns the gene PDCD1 and metastatic melanoma.